Bringing the fundamentals into focus…
Back to Gilead Sciences, Inc.
How Gilead Sciences, Inc. stacks up
GILD · against 454 other Healthcare companies listed in US-listed
Growth
26/ 100
Near the bottom of its peers.
Ranked #364 of 455 · scores higher than 19% of peers
Bars: peers in each 10-point band of the growth score34 peers with a growth score of 20–29, including GILD · Click a bar to see the companies
Why growth scores 26?
Weighted metrics compared with all Healthcare companies.Its metrics sit close to the Healthcare norm.
- 3-year revenue growth is close to the peer norm. 3-year revenue growth: 3.6% vs peer median 5.8%
- Revenue growth is close to the peer norm. Revenue growth: 5.5% vs peer median 6.1%
- Earnings per share turned from a profit to a loss. Earnings per share growth: — vs peer median 9.8%
Metric by metric
Position: dot = GILD, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | GILD | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Revenue growthHigher is better · 475 reported | 5.5% | 11.0% | 36% | 33% | |
| Earnings per share growthHigher is better · 171 reported | 1684.2% | 21.2% | 98% | 33% | |
| 3-year revenue growthHigher is better · 433 reported | 3.6% | 11.0% | 29% | 33% |
Ranking by growth score
Top 5 and the companies ranked around GILD| Rank | Company | Market cap | Growth | Overall |
|---|---|---|---|---|
| 1 | 464M USD | 100 | 53 | |
| 2 | 1.4B USD | 99 | 73 | |
| 2 | 433M USD | 99 | 81 | |
| 2 | 8.8B USD | 99 | 31 | |
| 2 | 90M USD | 99 | 27 | |
| 358 | 1.4B USD | 28 | 42 | |
| 358 | 11.9B USD |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score